Jafari Mehdi, Mousavi Seyed Masood, Asgharzadeh Asra, Yazdani Neda
Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran; Health Services Management Department, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Indian Heart J. 2018 Jul;70 Suppl 1(Suppl 1):S111-S117. doi: 10.1016/j.ihj.2018.01.031. Epub 2018 Jan 31.
This article is an attempt to provide an overview of systematic reviews to determine the efficacy of CQ10 supplementation in the treatment of patients with cardiovascular diseases (CVD).
All reviews were identified through a systematic search of the following databases: Cochrane, DARE, Ovid, EMBASE, ISI Web of Knowledge, and PubMed. Check references studies and the quality of the studies was assessed by means of AMSTTAR. No meta-analyses were performed due to the heterogeneity of studies.
Extracted data for Seven systematic reviews for primary outcomes, net changes in cardiac output, cardiac index, New York Heart Association functional classification, improved survival, based on existing evidence, there is a case for use of CoQ10 as an adjunctive therapy in congestive heart failure, especially in those patients unable to tolerate mainstream medical therapies.
Evidence suggests that the CoQ10 supplement may be a useful tool for managing patients with heart failure.
本文旨在对系统性综述进行概述，以确定补充辅酶Q10（CQ10）在治疗心血管疾病（CVD）患者中的疗效。
通过对以下数据库进行系统性检索来识别所有综述：Cochrane、DARE、Ovid、EMBASE、ISI Web of Knowledge和PubMed。检查参考文献研究，并使用AMSTTAR评估研究质量。由于研究的异质性，未进行荟萃分析。
提取了七项系统性综述的主要结局数据，包括心输出量、心脏指数的净变化、纽约心脏协会功能分级、生存率改善情况。基于现有证据，有理由将辅酶Q10用作充血性心力衰竭的辅助治疗，尤其是在那些无法耐受主流药物治疗的患者中。
证据表明，补充辅酶Q10可能是管理心力衰竭患者的有用工具。
